Startups
2017
NANOLIGENT SLDesigning precision medicines
State-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy
State-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy
Address
Avinguda de Can Domènech, 08193 Cerdanyola del Vallès, Spain
Finance Data
CERCA ownership
Barcelona, Spain
1992
Institut de Recerca Sant Pau
Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics.
Product description
Our technology allows the design of new protein conjugates organized as nanoparticles and capable of targeting specific biological systems. This protein architecture is highly stable upon administration in vivo, allowing not only long-lasting systemic circulation but also site-specific drug delivery. Precision medicine aiming high therapeutic index and low side effects for oncology.
Nano-sized: Our proteins have the capacity to self-assamble and form nanoparticles that avoid kidney clearance.
Targeted: By means of a specific ligand, Nanoligent’s medicine is able to selectively target cells, delivering the desired cargo
Humanized scaffolds: We have developed humanized scaffolds for our medicine to avoid undesired immune responses.
Protein-only: Our technology involves protein-only nanoparticles that can be degraded naturally in the body.
Cell-killing: Drug conjugation allow our nanoparticles to kill cells while retaining the selectivity. Thus, there is a reduction in systemic toxicity.
Nano-sized: Our proteins have the capacity to self-assamble and form nanoparticles that avoid kidney clearance.
Targeted: By means of a specific ligand, Nanoligent’s medicine is able to selectively target cells, delivering the desired cargo
Humanized scaffolds: We have developed humanized scaffolds for our medicine to avoid undesired immune responses.
Protein-only: Our technology involves protein-only nanoparticles that can be degraded naturally in the body.
Cell-killing: Drug conjugation allow our nanoparticles to kill cells while retaining the selectivity. Thus, there is a reduction in systemic toxicity.